88,148 Shares in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Purchased by Exome Asset Management LLC

Exome Asset Management LLC purchased a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 88,148 shares of the company’s stock, valued at approximately $797,000.

Several other hedge funds have also bought and sold shares of LXEO. BNP Paribas Financial Markets lifted its stake in shares of Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period. Values First Advisors Inc. purchased a new position in Lexeo Therapeutics in the third quarter valued at $67,000. Rhumbline Advisers boosted its stake in shares of Lexeo Therapeutics by 37.3% during the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after acquiring an additional 3,627 shares in the last quarter. MetLife Investment Management LLC increased its stake in shares of Lexeo Therapeutics by 121.5% in the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock valued at $129,000 after purchasing an additional 7,803 shares in the last quarter. Finally, PDT Partners LLC acquired a new position in Lexeo Therapeutics in the 3rd quarter worth about $241,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on LXEO. Leerink Partners reduced their price target on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. Chardan Capital raised their target price on Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright boosted their price target on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $23.80.

Insider Buying and Selling at Lexeo Therapeutics

In other news, CEO Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total transaction of $40,500.00. Following the sale, the chief executive officer now owns 120,695 shares of the company’s stock, valued at approximately $977,629.50. The trade was a 3.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 10,000 shares of company stock worth $80,550 in the last three months. 4.50% of the stock is owned by corporate insiders.

Lexeo Therapeutics Price Performance

LXEO stock opened at $6.88 on Friday. Lexeo Therapeutics, Inc. has a 1 year low of $5.77 and a 1 year high of $22.33. The firm has a market capitalization of $227.49 million and a PE ratio of -2.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The business has a 50 day simple moving average of $8.13 and a 200-day simple moving average of $11.36.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.